Skip to main content
Improve Medical Instruments CO., Ltd. logo

Improve Medical Instruments CO., Ltd. — Investor Relations & Filings

Ticker · 300030 ISIN · CNE100000JL3 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,954 across all filing types
Latest filing 2023-04-26 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 300030

About Improve Medical Instruments CO., Ltd.

https://www.improve-medical.com

Improve Medical Instruments CO., Ltd. focuses on the development, production, and distribution of clinical laboratory and nursing solutions. The core product range includes evacuated blood collection systems, specimen collection and transport media, and laboratory automation equipment. The company also provides medical imaging components and point-of-care testing (POCT) systems. By integrating research and development with advanced manufacturing, the organization supports clinical diagnostics and patient care through high-precision tools designed for healthcare facilities and research laboratories. Its offerings are characterized by a commitment to diagnostic safety and efficiency across global markets.

Recent filings

Filing Released Lang Actions
关于2022年度计提资产减值准备的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding the company's asset impairment provisions for the fiscal year 2022. It details the amounts and methods of impairment for various asset categories such as credit impairment, inventory write-downs, intangible assets, and goodwill. It also describes the approval process by the board and supervisory committee and mentions audit confirmation. The document is relatively short (2906 characters) and primarily serves as a formal announcement of the impairment provisions rather than a full financial report. It does not contain comprehensive financial statements or detailed financial analysis typical of an Annual Report (10-K) or Interim Report (IR). It is not a certification letter or a regulatory compliance filing. Given the content and length, this document fits best as a Regulatory Filing (RNS) because it is a formal disclosure of a significant accounting event but not a full report or a meeting material or voting result announcement.
2023-04-26 Chinese
2022年年度报告
Annual Report Classification · 100% confidence The document is titled as the "2022 年年度报告全文" (2022 Annual Report Full Text) of 阳普医疗科技股份有限公司, indicating it is a full annual report. It contains detailed sections including company overview, financial data, management discussion and analysis, governance, environmental and social responsibility, and financial statements. The document includes signatures from company officers and auditors, detailed financial metrics for the year 2022, and extensive narrative on business operations and industry context. The length is substantial (15,000 characters), and it is not merely an announcement or a certification. The content matches the characteristics of an official yearly report covering company activity and full financial performance, which corresponds to the Annual Report (10-K) filing type. FY 2022
2023-04-26 Chinese
关于变更对广州阳普医疗器械有限公司的出资方式的公告
Share Issue/Capital Change Classification · 95% confidence The document is an announcement regarding a change in the capital contribution method to a subsidiary company, Guangzhou Yangpu Medical Device Co., Ltd. It details the change in the form of capital injection (from fixed assets and intangible assets to monetary contributions) without altering the registered capital or shareholding structure. The document includes board and supervisory meeting resolutions approving the change. It is a corporate announcement about capital structure changes rather than a full financial report or detailed financial statements. The document length is short (2143 characters), and it is not a report itself but an announcement of a corporate action related to capital contribution. Therefore, it fits best under the category of Share Issue/Capital Change (SHA).
2023-04-26 Chinese
2022年度监事会工作报告
Audit Report / Information Classification · 95% confidence The document is titled as the "2022年度监事会工作报告" (2022 Supervisory Board Work Report) of 阳普医疗科技股份有限公司. It details the supervisory board's activities, meetings, and oversight of the company's operations, financials, internal controls, and governance during the 2022 fiscal year. It includes specific references to the supervisory board's review of the 2022 annual report and financial statements, internal control evaluations, and other governance matters. The document is a comprehensive report from the supervisory board rather than an announcement or a brief summary. It does not fit the Annual Report (10-K) category as it is a supervisory board report, nor is it a simple announcement or certification. It is not a management report or earnings release but a formal supervisory board work report, which aligns with the Audit Report / Information (AR) category, as it includes audit opinions and supervisory oversight information. The document length is 3005 characters, which is sufficient for a detailed report but not overly brief to be an announcement. Therefore, the best fit is Audit Report / Information (AR). FY 2022
2023-04-26 Chinese
独立董事关于第五届董事会第二十一次会议相关事项的事前认可意见
Board/Management Information Classification · 95% confidence The document is a formal opinion letter from independent directors regarding matters to be discussed at the 21st meeting of the 5th board of directors of Yangpu Medical Technology Co., Ltd. It includes pre-approval opinions on routine related-party transactions and the reappointment of an audit firm for the 2023 fiscal year. The document is short (848 characters) and does not contain financial statements or detailed financial data. It is not a full audit report or annual report but rather a governance-related document expressing independent directors' opinions on board meeting agenda items. This fits best under Board/Management Information (MANG), which covers announcements related to board matters and management decisions. The document is not a report publication announcement or regulatory filing since it contains substantive content from independent directors. Therefore, the classification is MANG with high confidence.
2023-04-26 Chinese
关于2022年度拟不进行利润分配的专项说明
Notice of Dividend Amount Classification · 95% confidence The document is a formal announcement from the company 阳普医疗科技股份有限公司 regarding its 2022 annual profit distribution plan, specifically stating that no dividends will be distributed for the year 2022. It includes details about the company's net profit, reasons for not distributing profits, and opinions from independent directors and the supervisory board. The document is relatively short (1618 characters) and focuses on the profit distribution proposal and related explanations rather than presenting full financial statements or comprehensive financial performance data. It is not an annual report (10-K), interim report (IR), or earnings release (ER). Instead, it is an announcement related to dividend distribution plans and shareholder information. Given the content and length, the best fitting category is Notice of Dividend Amount (DIV), as it announces the dividend distribution decision and related details for shareholders.
2023-04-26 Chinese

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.